Development of an assay- and screening-platform to study molecular glue degraders

Discover how targeting RNA-binding motif protein 39 (RBM39) is unlocking new possibilities in cancer treatment. RBM39, a key player in transcriptional regulation, alternative splicing, and protein translation, is critical to the growth of several cancers. Its inhibition has shown to be lethal in lung, breast, and colorectal cancers, making it a powerful emerging target for cancer diagnostics and therapy.

 

Join our upcoming webinar, where experts from Abbvie and Fraunhofer ITMP will share insights into the use of molecular glue degraders and advanced HTRF (Homogeneous Time-Resolved Fluorescence) technology to quantify RBM39 degradation in neuroblastoma (SH-SY5Y) cancer cells. Learn how this approach is transforming cancer research, optimizing dosing, and paving the way for innovative treatments.

 

Get an exclusive look at how Fraunhofer ITMP is integrating automated HTRF workflows to screen for molecular degraders, using both recombinant and endogenous proteins, in 384-well plate format. Explore the future of targeted cancer therapies with us!

 

Learning Objectives